Literature DB >> 14636690

Relationship between the Pfcrt T76 and the Pfmdr-1 Y86 mutations in Plasmodium falciparum and in vitro/in vivo chloroquine resistance in Burkina Faso, West Africa.

Halidou Tinto1, Jean Bosco Ouédraogo, Annette Erhart, Chantal Van Overmeir, Jean-Claude Dujardin, Eric Van Marck, Tinga Robert Guiguemdé, Umberto D'Alessandro.   

Abstract

The relationship between Pfcrt T76 and Pfmdr-1 Y86 mutations in Plasmodium falciparum was explored in samples from patients with uncomplicated malaria and tested in vitro and in vivo with chloroquine (CQ) in Burkina Faso. The two mutations were strongly related. The Pfcrt T76 mutation was found in 82% of the samples having the Pfmdr-1 Y86 mutation too (odds ratio (OR)=4.8 [95% CI: 1.7-13.3]; P=0.002). However, only half (16/34) of samples with Pfcrt T76 mutation had also the Pfmdr-1 Y86 mutation. The latter was apparently associated with in vitro resistance (OR=4.8 [95% CI: 1.4-16.5]; P=0.01) but such association disappeared (P=0.77) after adjusting for the presence of the Pfcrt T76 mutation. This suggests that the occurrence of the Pfmdr-1 Y86 mutation is dependent on that of Pfcrt T76 mutation and could explain previous reports linking the Pfmdr-1 Y86 mutation with CQ resistance (CQR). The isolates carrying both the Pfcrt K76 and Pfmdr-1 N86 alleles (wild/wild (WW)) and the single mutant Pfmdr-1 Y86 (WM) had the lowest IC50 geometric mean (GMIC50) values, while those carrying both Pfcrt T76/Pfmdr-1 Y86 alleles (mutant/mutant (MM)), and the single mutant Pfcrt T76 (MW) had the highest. Among pre-treatment samples there was a strong linkage disequilibrium with an excess of MM and WW and a deficit of single mutants (MW and WM), suggesting that parasite fitness is higher for the former and lower for the latter.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14636690     DOI: 10.1016/j.meegid.2003.08.002

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  15 in total

1.  In vivo selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso.

Authors:  Vito Baraka; Halidou Tinto; Innocent Valea; Robert Fitzhenry; Christopher Delgado-Ratto; Martin K Mbonye; Chantal Van Overmeir; Anna Rosanas-Urgell; Jean-Pierre Van Geertruyden; Umberto D'Alessandro; Annette Erhart
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

2.  A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance.

Authors:  Viswanathan Lakshmanan; Patrick G Bray; Dominik Verdier-Pinard; David J Johnson; Paul Horrocks; Rebecca A Muhle; George E Alakpa; Ruth H Hughes; Steve A Ward; Donald J Krogstad; Amar Bir Singh Sidhu; David A Fidock
Journal:  EMBO J       Date:  2005-06-09       Impact factor: 11.598

3.  In vivo and in vitro analysis of chloroquine resistance in Plasmodium falciparum isolates from Senegal.

Authors:  Ousmane Sarr; Alissa Myrick; Johanna Daily; Bernard M Diop; Therese Dieng; Omar Ndir; Pape Salif Sow; Souleymane Mboup; Dyann F Wirth
Journal:  Parasitol Res       Date:  2005-06-29       Impact factor: 2.289

4.  A molecular map of chloroquine resistance in Mali.

Authors:  Abdoulaye A Djimde; Breanna Barger; Aminatou Kone; Abdoul H Beavogui; Mamadou Tekete; Bakary Fofana; Antoine Dara; Hamma Maiga; Demba Dembele; Sekou Toure; Souleymane Dama; Dinkorma Ouologuem; Cheick Papa Oumar Sangare; Amagana Dolo; Nofomo Sogoba; Karamoko Nimaga; Yacouba Kone; Ogobara K Doumbo
Journal:  FEMS Immunol Med Microbiol       Date:  2009-11-02

5.  Role of Pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine, and dihydroartemisinin.

Authors:  Nathalie Wurtz; Bécaye Fall; Aurélie Pascual; Mansour Fall; Eric Baret; Cheikhou Camara; Aminata Nakoulima; Bakary Diatta; Khadidiatou Ba Fall; Pape Saliou Mbaye; Yaya Diémé; Raymond Bercion; Boubacar Wade; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2014-09-08       Impact factor: 5.191

6.  Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal.

Authors:  Nathalie Wurtz; Bécaye Fall; Aurélie Pascual; Silmane Diawara; Kowry Sow; Eric Baret; Bakary Diatta; Khadidiatou B Fall; Pape S Mbaye; Fatou Fall; Yaya Diémé; Christophe Rogier; Raymond Bercion; Sébastien Briolant; Boubacar Wade; Bruno Pradines
Journal:  Malar J       Date:  2012-06-13       Impact factor: 2.979

7.  High frequency of Plasmodium falciparum chloroquine resistance marker (pfcrt T76 mutation) in Yemen: an urgent need to re-examine malaria drug policy.

Authors:  Abdulsalam M Al-Mekhlafi; Mohammed A K Mahdy; Hesham M Al-Mekhlafi; Ahmed A Azazy; Mun Yik Fong
Journal:  Parasit Vectors       Date:  2011-05-27       Impact factor: 3.876

8.  Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study.

Authors:  Bécaye Fall; Aurélie Pascual; Fatoumata D Sarr; Nathalie Wurtz; Vincent Richard; Eric Baret; Yaya Diémé; Sébastien Briolant; Raymond Bercion; Boubacar Wade; Adama Tall; Bruno Pradines
Journal:  Malar J       Date:  2013-03-20       Impact factor: 2.979

Review 9.  A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria.

Authors:  Stéphane Picot; Piero Olliaro; Frédérique de Monbrison; Anne-Lise Bienvenu; Ric N Price; Pascal Ringwald
Journal:  Malar J       Date:  2009-05-04       Impact factor: 2.979

10.  The usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New Guinea.

Authors:  Jutta Marfurt; Ivo Müller; Albert Sie; Olive Oa; John C Reeder; Thomas A Smith; Hans-Peter Beck; Blaise Genton
Journal:  Malar J       Date:  2008-04-19       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.